You are here: Industry Insights > chronic cough

News List

A Brief Overview of Research Progress in Therapeutic Targets for Chronic Cough Xiaomichong
July 15, 2024
Cough is a complex neurophysiological reflex. Cough receptors, in the form of receptors and ion channels, are located at the sensory nerve endings of the airway.
A Brief Introduction to Drug Treatment and New Drug Development for Chronic Cough Xiaomichong
July 15, 2024
Chronic cough (CC) is a common disease with a prevalence rate of up to 12%, significantly affecting the quality of life of patients.
FDA issues complete response letter for Merck’s chronic cough treatment Pharmaceutical-Technology
January 26, 2022
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Merck’s (MSD) New Drug Application (NDA) for gefapixant to treat adults with refractory chronic cough (RCC) or unexplained chronic cough (UCC).
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough drugs.com
September 24, 2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant...
Higher dose of gefapixant hits endpoints in chronic cough trial pharmatimes
March 19, 2020
MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough.
P2X3 agonist shows promise in relieving chronic cough pharmaceutical-technology
March 04, 2020
A Phase IIb study by researchers at the University of Manchester, UK, has demonstrated that P2X3 agonist gefapixant relieves refractory or unexplained chronic cough.
BELLUS Health Announces Positive Top-Line Phase 1 Results For Chronic Cough seekingalpha
November 27, 2018
On November 19, BELLUS Health announced positive top-line Phase 1 clinical trial results for its chronic cough candidate BLU-5937....
Menlo Therapeutics' cough drug fails to meet primary endpoint in phase II trial pharmafile
November 20, 2018
The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant